Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC
NCT00633529
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
36
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG:
IMO-2055
Sponsor
EMD Serono